[go: up one dir, main page]

WO2010124089A3 - Nepicastat for treating dependence - Google Patents

Nepicastat for treating dependence Download PDF

Info

Publication number
WO2010124089A3
WO2010124089A3 PCT/US2010/032052 US2010032052W WO2010124089A3 WO 2010124089 A3 WO2010124089 A3 WO 2010124089A3 US 2010032052 W US2010032052 W US 2010032052W WO 2010124089 A3 WO2010124089 A3 WO 2010124089A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
nepicastat
dependence
substance
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/032052
Other languages
French (fr)
Other versions
WO2010124089A2 (en
Inventor
Michael Mulqueen
Mark Moran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synosia Therapeutics Inc
Original Assignee
Synosia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synosia Therapeutics Inc filed Critical Synosia Therapeutics Inc
Publication of WO2010124089A2 publication Critical patent/WO2010124089A2/en
Publication of WO2010124089A3 publication Critical patent/WO2010124089A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided are methods of treating patients suffering from or susceptible to at least one symptom of abuse of, dependence on, or withdrawal from at least one substance with nepicastat in combination with psychosocial therapy. Also provided are methods of treating at least one phase of substance dependence on at least one substance in patients and certain methods of treating at least one phase of cocaine dependence in patients.
PCT/US2010/032052 2009-04-22 2010-04-22 Methods for treating dependence Ceased WO2010124089A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17155209P 2009-04-22 2009-04-22
US61/171,552 2009-04-22

Publications (2)

Publication Number Publication Date
WO2010124089A2 WO2010124089A2 (en) 2010-10-28
WO2010124089A3 true WO2010124089A3 (en) 2010-12-16

Family

ID=42829358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/032052 Ceased WO2010124089A2 (en) 2009-04-22 2010-04-22 Methods for treating dependence

Country Status (1)

Country Link
WO (1) WO2010124089A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US20160279124A1 (en) * 2015-03-27 2016-09-29 Dan Markel Method for Treating Addiction
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN113993522A (en) 2019-04-17 2022-01-28 指南针探路者有限公司 Method for treating anxiety disorders, headache disorders and eating disorders with siloxibin
CN111018663A (en) * 2019-12-02 2020-04-17 苏州凯瑞医药科技有限公司 Nepitastat important intermediate and enzyme catalytic synthesis method thereof
PH12022553135A1 (en) 2020-05-19 2024-03-04 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
CN116270519A (en) * 2022-02-21 2023-06-23 南京纽邦生物科技有限公司 Softgels Containing Beta-Hydroxybutyric Acid
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021055A1 (en) * 2007-08-06 2009-02-12 Synosia Therapeutics, Inc. Methods for treating dependence

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021055A1 (en) * 2007-08-06 2009-02-12 Synosia Therapeutics, Inc. Methods for treating dependence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"ClinicalTrials Identifier: NCT00656357. Study of Safety and Potential Efficacy of SYN117 in Cocaine Dependent Volunteers", 10 April 2008 (2008-04-10), XP002604280, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00656357/2008_04_10> [retrieved on 20101008] *

Also Published As

Publication number Publication date
WO2010124089A2 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
WO2010124089A3 (en) Nepicastat for treating dependence
MX2010001390A (en) Methods for treating dependence.
IL220040A0 (en) Methods and low dose regimens for treating red blood cell disorders
WO2009109911A8 (en) Methods of treating chronic pain
WO2012062925A3 (en) Compounds and methods for treating pain
WO2008153730A3 (en) Method for treating proliferative disorders associated with mutations in c-met
WO2009109908A8 (en) Methods of treating inflammatory pain
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
AP2011005824A0 (en) Methods for treating acute myocardial infarctions and associated disorders.
WO2009124133A3 (en) Security features for a medical infusion pump
EP2362726A4 (en) Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
IL207792A0 (en) Methods, dosage forms, and kits for administering ziprasidone without food
WO2010068523A3 (en) Dual metal interconnects for improved gap-fill, reliability, and reduced capacitance
WO2010088450A3 (en) Arylamide derivatives useful in the treatment of diseases associated with serca activity
EP2413837A4 (en) Methods for treating myofascial, muscle, and/or back pain
WO2012027326A9 (en) Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
MX359930B (en) Methods of treatment.
WO2012082821A3 (en) Melanoma treatments
WO2011050351A3 (en) Methods and kits used in identifying glioblastoma
PL2604691T3 (en) Means and methods for counteracting, delaying and/or preventing adverse energy metabolism switches in heart disease
WO2008115478A3 (en) Method of cancer detection and treatment
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
WO2011041325A3 (en) Methods and compositions for the treatment of viral disorders
EP2371340A4 (en) Instrument for alleviating addictive drug craving, method for using same and method for treating addictive drug dependence

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10715637

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10715637

Country of ref document: EP

Kind code of ref document: A2